



## **Advicenne announces its upcoming participation in two of the most important international investor conferences**

**Paris, France, November 3, 2022 – 6.00 PM (CET)** – Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, today announces today its participation in two major international healthcare investor conferences:

- **Jefferies London Healthcare Conference**, London, November 15-17, 2022
- **J.P. Morgan Health Care Conference**, San Francisco, January 9-12, 2023

*"Our participation in the two largest conferences in our industry gives us the opportunity to meet with the most demanding investors as well as the leading players in business development. This year, our presence in London and San Francisco takes on a special meaning in the context of the sustained commercial deployment of Sibnaya<sup>®</sup> in Europe and the research for an American partner for the co-development and marketing of this treatment across the Atlantic. The many meetings already scheduled with major names confirm the interest in our flagship product and, more generally, in Advicenne»,* said Didier Laurens, Chief Executive Officer of Advicenne.

### **About Advicenne**

Advicenne (Euronext: ALDVI) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnaya<sup>®</sup> (ADV 7103) has received its Marketing Approval for distal renal tubular acidosis in EU and the UK. ADV 7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US and in Canada. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022. **For additional information see:** <https://advicenne.com/>.



## CONTACTS

### Advicenne

Didier Laurens, CEO

+33 (0)1 87 44 40 17

Email: [investors@advicenne.com](mailto:investors@advicenne.com)

### Ulysse Communication

Media relations

Bruno Arabian

+33 (0)6 87 88 47 26

Email: [barabian@ulysse-communication.com](mailto:barabian@ulysse-communication.com)

### Disclaimer

*This press release contains certain forward-looking statements concerning Advicenne group and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Advicenne considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 2021 Universal Registration Document filed with the French financial market authority on April 29, 2022 (a copy of which is available on [www.advicenne.com](http://www.advicenne.com)) and to the development of economic conditions, financial markets, and the markets in which Advicenne operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Advicenne or not currently considered material by Advicenne. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of Advicenne to be materially different from such forward-looking statements. Advicenne expressly declines any obligation to update such forward-looking statements.*